CSIMarket
 
Amphastar Pharmaceuticals Inc   (NASDAQ: AMPH)
 
Price: $23.8400 $0.10 0.421%
Day's High: $23.920000076293945 Week Perf: 8.31 %
Day's Low: $ 23.04 30 Day Perf: 17.79 %
Volume (M): 469,750 52 Wk High: $ 29.78
Volume (M$): $ 0 52 Wk Avg: $23.23
Open: $23.92 52 Wk Low: $16.65



 Market Capitalization (Millions $) 1,108
 Shares Outstanding (Millions) 46
 Employees 1,976
 Revenues (TTM) (Millions $) 721
 Net Income (TTM) (Millions $) 79
 Cash Flow (TTM) (Millions $) -12
 Capital Exp. (TTM) (Millions $) 36

Business Description


Amphastar Pharmaceuticals Inc is a publicly traded American pharmaceutical company founded in 1996 by Drs. Jack and Rex Zhang. The company is headquartered in Rancho Cucamonga, California and has a market capitalization of over $1 billion. Amphastar specializes in the development, manufacturing, and marketing of generic and proprietary injectable and inhalation products.

The company has more than 20 injectable products in its portfolio, which includes anesthesia, analgesics, anti-infectives, cardiovascular, and central nervous system agents. Amphastar's most significant revenue generating product is enoxaparin sodium injection, a generic version of Sanofi's anticoagulant Lovenox. This product accounts for more than 50% of the company's total revenue.

Additionally, Amphastar has branded products, such as Primatene Mist, an over-the-counter inhaler used for the treatment of asthma symptoms. The company also has a pipeline of innovative products, including products in clinical trials for diabetes, hypoglycemia, and severe allergies.

The company has three manufacturing facilities located in California, which are equipped with the latest manufacturing technology and conform to the highest regulatory standards of the FDA and the European Medicines Agency (EMA).

In addition to its manufacturing capabilities, Amphastar has a robust research and development team that is responsible for developing new products and improving existing products. The company invests heavily in research and development, spending around 20% of its revenue on these activities.

Amphastar has a global presence and has distribution partnerships in many countries, including the United States, Europe, and Asia. The company has a diverse customer base that includes hospitals, wholesalers, and distributors.

Amphastar is committed to corporate social responsibility and strives to reduce its impact on the environment. The company has implemented sustainability programs that focus on energy efficiency, water conservation, and waste management.

In summary, Amphastar Pharmaceuticals is a leading pharmaceutical company that specializes in the development, manufacturing, and marketing of generic and proprietary injectable and inhalation products. With a wide range of products, an innovative pipeline, and a strong commitment to sustainability, Amphastar is poised for continued growth and success in the pharmaceutical industry.


   Company Address: 11570 6th Street Rancho Cucamonga 91730 CA
   Company Phone Number: 980-9484   Stock Exchange / Ticker: NASDAQ AMPH


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMRX   -0.78%    
PFE        2.82% 
PRGO   -0.7%    
RDY   -1.07%    
TEVA   -2.66%    
VTRS        0.3% 
• View Complete Report
   





Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 14.36
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 1.54
Price to Sales (Expected) -
Price to Book 1.43
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.79
Working Capital Ratio 3.85
Leverage Ratio (MRQ) 1.13
Total Debt to Equity 0.79
Interest Coverage (TTM) -
Debt Coverage (TTM) 0.27

Per Share Current
Earnings (TTM) 1.66 $
Revenues (TTM) 15.51 $
Cash Flow (TTM) -
Cash 6.33 $
Book Value 16.65 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 364,641
Net Income per Employee (TTM) 40,096
Receivable Turnover Ratio (TTM) 5.05
Inventory Turnover Ratio (TTM) 2.09
Asset Turnover Ratio (TTM) 0.44

Profitability Ratios Current
Gross Margin (MRQ) 41.08 %
Operating Margin (MRQ) 7.96 %
Net Margin (MRQ) 3.75 %
Net Cash Flow Margin (MRQ) 0.45 %
Effective Tax Rate (TTM) 22.94 %

Management Effectiveness Current
Return On Assets (TTM) 4.83 %
Return On Investment (TTM) 5.41 %
Return On Equity (TTM) 10.23 %
Dividend Yield -
Pay out Ratio (TTM) -



Amphastar Pharmaceuticals Inc's Segments
Research and development services ANP    1.46 % of total Revenue
Accounts Receivable    19.46 % of total Revenue
Accounts Payable and Accrued Liabilities    19.24 % of total Revenue
Pharmaceutical products segment    100 % of total Revenue
Finished Pharmaceutical Products Segment    100 % of total Revenue
Finished Pharmaceutical Products Glucagon    5.36 % of total Revenue
Finished Pharmaceutical Products Primatene MIST    17.39 % of total Revenue
Finished Pharmaceutical Products BAQSIMI    18.95 % of total Revenue
Finished Pharmaceutical Products Epinephrine    11.22 % of total Revenue
Finished Pharmaceutical Products Lidocaine    7.86 % of total Revenue
Finished Pharmaceutical Products Other Products    39.22 % of total Revenue
UNITED STATES    92.91 % of total Revenue
China    1.45 % of total Revenue
France    5.64 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.